Provention Bio, Inc. (PRVB) financial statements (2022 and earlier)

Company profile

Business Address 55 BROAD STREET, 2ND FLOOR
RED BANK, NJ 07701
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments95,111150,773176,378207,205121,824147,158172,155
Cash and cash equivalents78,190139,340151,781180,357102,294118,439145,887
Short-term investments16,92111,43324,59726,84819,53028,71926,268
Other undisclosed current assets5,9854,4924,2094,4464,7304,173 
Total current assets:101,096155,265180,587211,651126,554151,331172,155
Noncurrent Assets
Operating lease, right-of-use asset373384393401408  
Property, plant and equipment2,0112,1062,2081,6141,437352 
Long-term investments and receivables32,021      
Long-term investments32,021      
Other noncurrent assets120120120120120120 
Total noncurrent assets:34,5252,6102,7212,1351,965472 
Other undisclosed assets      3,600
TOTAL ASSETS:135,621157,875183,308213,786128,519151,803175,755
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17,19215,31617,63322,23316,73016,40411,979
Accounts payable3,5463,6333,8668,2837,5687,1057,828
Accrued liabilities13,64611,68313,76713,9509,1629,2994,151
Deferred revenue5,5995,4947,0004,519   
Total current liabilities:22,79120,81024,63326,75216,73016,40411,979
Noncurrent Liabilities
Long-term debt and lease obligation590624655686715  
Operating lease, liability590624655686715  
Liabilities, other than long-term debt1,5062,328 2,481   
Deferred revenue1,5062,328 2,481   
Other undisclosed noncurrent liabilities  (655) (715)  
Total noncurrent liabilities:2,0962,9526553,167   
Total liabilities:24,88723,76225,28829,91917,44516,40411,979
Stockholders' equity
Stockholders' equity attributable to parent110,734134,113158,020183,867111,074135,399163,776
Common stock6666666
Additional paid in capital402,941400,356397,226393,959288,725280,439277,437
Accumulated other comprehensive income (loss)(139)(3)12(16)(15)2098
Accumulated deficit(292,074)(266,246)(239,224)(210,082)(177,642)(145,066)(113,765)
Total stockholders' equity:110,734134,113158,020183,867111,074135,399163,776
TOTAL LIABILITIES AND EQUITY:135,621157,875183,308213,786128,519151,803175,755

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues717678     
Gross profit:717678     
Operating expenses(26,577)(27,755)(30,173)(32,468)(32,620)(31,406)(22,796)
Operating loss:(25,860)(27,077)(30,173)(32,468)(32,620)(31,406)(22,796)
Nonoperating income
(Investment Income, Nonoperating)
      151
Loss from continuing operations before equity method investments, income taxes:(25,860)(27,077)(30,173)(32,468)(32,620)(31,406)(22,645)
Other undisclosed income from continuing operations before income taxes3255312844105 
Loss from continuing operations before income taxes:(25,828)(27,022)(30,142)(32,440)(32,576)(31,301)(22,645)
Income tax benefit  1,000   523
Net loss available to common stockholders, diluted:(25,828)(27,022)(29,142)(32,440)(32,576)(31,301)(22,122)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(25,828)(27,022)(29,142)(32,440)(32,576)(31,301)(22,122)
Other comprehensive income (loss)(136)(15)28(1)(35)(78)(112)
Comprehensive loss, net of tax, attributable to parent:(25,964)(27,037)(29,114)(32,441)(32,611)(31,379)(22,234)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: